OnDemand Neuro-Ophthalmology Update 2024

Click Here to Register for the Livestream!

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

AMA PRA Statement
Wills Eye Hospital designates this Enduring Material for a maximum of 4.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

View a full list of faculty and disclosures here

Mitigation of Relevant Financial Relationships

In compliance with the Standards for Integrity and Independence in Accredited Continuing Education set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Wills Eye Hospital that the information presented at CME activities will be commercially unbiased and based upon clinical and scientific evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that all individuals in a position to control the content of a CME activity (including faculty, planners, reviewers or others) have disclosed about all financial relationships they have with ineligible companies. All relevant financial relationships have been mitigated.

Ineligible companies are companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. The CME activity staff at Wills Eye Hospital report no financial relationships with ineligible companies.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Danijel J Pericic, MD
Wills Eye Hospital

Planner

Nothing to disclose

Robert C Sergott, MD
Wills Eye Hospital

Planner

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Roche (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Amgen|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Heidelberg Engineering|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol Myers Squibb|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Clene Nanomedicine|Membership on Advisory Committees or Review Panels, Board Membership, etc.-GenSight Biologics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck (Relationship has ended)